文献速递认知障碍与痴呆帕金森病与运动障碍

特拉唑嗪、多沙唑嗪或阿夫唑嗪使用与男性路易体痴呆风险的相关性

Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men.
PubMed 文献 · Neurology · 2024-06-19

本研究采用新使用者活性对照设计,在Merative Marketscan数据库中匹配倾向评分和随访时长,比较男性使用特拉唑嗪/多沙唑嗪/阿夫唑嗪(Tz/Dz/Az)与使用坦索罗辛或5α-还原酶抑制剂(5ARI)的路易体痴呆(DLB)风险。结果显示Tz/Dz/Az组DLB风险低于坦索罗辛组(HR 0.60,95%CI 0.50-0.71)和5ARI组(HR 0.73,95%CI 0.57-0.93),坦索罗辛组与5ARI组风险相似(HR 1.17,95%CI 0.96-1.42)。作者认为糖酵解增强药物可能在突触核蛋白病中具有广泛保护作用,但需随机试验验证因果性。

要点

  • 男性使用Tz/Dz/Az者路易体痴呆风险低于坦索罗辛使用者(HR 0.60,95%CI 0.50-0.71)。
  • 男性使用Tz/Dz/Az者路易体痴呆风险低于5ARI使用者(HR 0.73,95%CI 0.57-0.93)。
  • 坦索罗辛使用者与5ARI使用者的路易体痴呆风险相似(HR 1.17,95%CI 0.96-1.42)。

核心结论

  • 在男性中,使用Tz/Dz/Az与较低的路易体痴呆风险相关。
  • 结合Tz/Dz/Az在帕金森病中的文献,糖酵解增强药物可能在突触核蛋白病中具有广泛保护作用。
  • 需要未来的随机试验来评估这些关联的因果性。

研究设计与样本

  • 采用新使用者活性对照设计,数据来源于Merative Marketscan数据库。
  • 纳入无路易体痴呆病史、新开始使用Tz/Dz/Az或对照药物的男性。
  • 对照药物为坦索罗辛或5α-还原酶抑制剂(5ARI)。
  • 按倾向评分和随访时长匹配队列,采用Cox比例风险回归估计路易体痴呆风险。

主要发现

  • Tz/Dz/Az组与坦索罗辛组比较:n=242,716,728,256人年,HR 0.60,95%CI 0.50-0.71。
  • Tz/Dz/Az组与5ARI组比较:n=130,872,399,316人年,HR 0.73,95%CI 0.57-0.93。
  • 坦索罗辛组与5ARI组比较:n=159,596,482,280人年,HR 1.17,95%CI 0.96-1.42。
  • 上述结果在多项敏感性分析中稳健。

关键数值与推荐

  • 本研究提供III级证据表明Tz/Dz/Az使用降低成年男性路易体痴呆的发生率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要未来的随机试验来评估这些关联的因果性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Terazosin, doxazosin, and alfuzosin (Tz/Dz/Az) are α-1 adrenergic receptor antagonists that also bind to and activate a key adenosine triphosphate (ATP)-producing enzyme in glycolysis. It is hypothesized that the increase in energy availability in the brain may slow or prevent neurodegeneration, potentially by reducing the accumulation of alpha-synuclein. Recent work has suggested a potentially neuroprotective effect of the use of Tz/Dz/Az in Parkinson disease in both animal and human studies. We investigated the neuroprotective effects of Tz/Dz/Az in a closely related disease, dementia with Lewy bodies (DLB). METHODS: We used a new-user active comparator design in the Merative Marketscan database to identify men with no history of DLB who were newly started on Tz/Dz/Az or 2 comparator medications. Our comparator medications were other drugs commonly used to treat benign prostatic hyperplasia that do not increase ATP: the α-1 adrenergic receptor antagonist tamsulosin or 5α-reductase inhibitor (5ARI). We matched the cohorts on propensity scores and duration of follow-up. We followed up the matched cohorts forward to estimate the hazard of developing DLB using Cox proportional hazards regression. RESULTS: Men who were newly started on Tz/Dz/Az had a lower hazard of developing DLB than matched men taking tamsulosin (n = 242,716, 728,256 person-years, hazard ratio [HR] 0.60, 95% CI 0.50-0.71) or 5ARI (n = 130,872, 399,316 person-years, HR 0.73, 95% CI 0.57-0.93). while the hazard in men taking tamsulosin was similar to that of men taking 5ARI (n = 159,596, 482,280 person-years, HR 1.17, 95% CI 0.96-1.42). These results were robust to several sensitivity analyses. DISCUSSION: We find an association in men who are taking Tz/Dz/Az and a lower hazard of DLB compared with similar men taking other medications. When combined with the literature of Tz/Dz/Az on Parkinson disease, our findings suggest that glycolysis-enhancing drugs may be broadly protective in neurodegenerative synucleinopathies. A future randomized trial is required to assess these associations for causality. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that Tz/Dz/Az use reduces the rate of developing DLB in adult men.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hart A, Aldridge G, Zhang Q, et al. Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men. Neurology. 2024. PMID: 38896813. doi:10.1212/WNL.0000000000209570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。